drugset / Trial / NCT07660796

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

NCT07660796

Phase 3 Not yet recruiting 256 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Timeline

Start
2026-07-06
Primary completion
2027-10-30
Completion
2027-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1803-3 Unknown Oral
Subject HCP1803-4 Unknown Oral
Comparator RLD2001-1 Unknown Oral
Comparator RLD2001-2 Unknown Oral